Search | Clinical Trials Finder

Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Interventions: Imipenem/Cilastatin/Relebactam; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 12 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Hartford, Connecticut • Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Kaletra + Current Dual NRTI Backbone, Current Regimen; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma in Children
Interventions: Ipratropium Bromide; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 2 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Buffalo, New York • Charlotte, North Carolina • Salt Lake City, Utah

Conditions: Major Depressive Episode
Interventions: Medibio Depression Diagnostic Aid, Mini International Neuropsychiatric Interview, Hamilton Rating Scale for Depression - 17 Item; Diagnostic Test
Lead sponsor: Medibio Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Garden Grove, California • Torrance, California • Mason, Ohio + 3 more

Conditions: Schizophrenia
Interventions: Drug: EVP-6308, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: HIV Infection, Hyperlipidemia
Interventions: Atazanavir, current antiretroviral regimen; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: Breast Cancer
Interventions: chemotherapy; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 296
States / cities: Anniston, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 210 more

Conditions: Administration and Dosage of Ketamine, Endoscopic Sedation
Interventions: Ketamine, Midazolam injection, Fentanyl; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Heart Failure
Interventions: Torsemide, Standard Outpatient Heart Failure Management; Drug · Other
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 18 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Atrial Fibrillation
Interventions: Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation; Drug · Other · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Adult Subjects
Interventions: Losmapimod 15 mg oral tablet, Losmapimod two 7.5 mg oral tablets, Losmapimod one 15 mg oral tablet; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertension, COVID
Interventions: ACEI/ARB, Non-ACEI/ARB, ACEI, ARB; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 22,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tuberculosis, HIV Infections
Interventions: Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6); Drug · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 21
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 17 more

Conditions: Cancer, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions: Fludarabine, Cyclophosphamide, Transplantation; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 4 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Interventions: Busulfan, Cyclophosphamide, Fludarabine, rabbit ATG, G-CSF, Peripheral blood stem cell; Drug · Biological
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Months and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 3
States / cities: New York, New York • Cincinnati, Ohio • Seattle, Washington

Conditions: Infection, Human Immunodeficiency Virus
Interventions: ABC/DTG/3TC FDC, Ongoing cART regimen; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 87
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more

Conditions: Solid Tumors, Hematologic Malignancies
Interventions: Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 65
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more

Conditions: Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy; Drug · Other · Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 4 more

Conditions: Hemophilia A, Hemophilia B
Interventions: ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant]); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more

Conditions: Diabetes Mellitus Type I, Diabetes Mellitus Type II
Interventions: EHR Based Strategy to promote Safe and Appropriate Drug Use; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: HIV-1 Infection
Interventions: Vesatolimod, Placebo, ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more

Conditions: Leukemia, Acute Lymphoblastic
Interventions: Acute Lymphobastic Leukemia (ALL) Treatment Options; Other
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years · Male only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 9 more

Conditions: PTSD, Alcohol; Use, Problem
Interventions: Seeking Safety + Signs of Safety toolkit, Treatment as usual; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Search by objective public record fields.

Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

Treating Respiratory Emergencies in Children Study

Medibio DDA Confirmatory Performance Study

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo

Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

Weight-Based Torsemide Dosing in Subjects With Heart Failure

Liraglutide Effect in Atrial Fibrillation

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses

Metabolic Abnormalities - HIV Infected and Uninfected Males

Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma